Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00527605
Status:
COMPLETED
Last Update Posted:
2012-03-21
First Post:
2007-09-10
Brief Title:
Dutasteride 05mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia BPH
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Six-month Parallel-group Study to Assess Efficacy and Safety of Dutasteride 05mg Once Daily in Chinese Patients With Benign Prostatic Hyperplasia BPH Followed by a 12-month Open-label Treatment Phase
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This randomized double-blind placebo-controlled six-month parallel-group study assess efficacy and safety of dutasteride 05mg once daily in Chinese patients with Benign Prostatic Hyperplasia BPH followed by a 12-month open-label treatment phase
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None